Company / Cash & Equivalents
ENvue Medical, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$4.2M
FY2025
5-year range
$4.2M / $7.7M
FY2021-FY2025
Trend
-
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $7M to $4M over the past 5 years.
Based on SEC 10-K filings.
$4M in FY2025 with a 5-year CAGR of -10.0%.
Declined from $7M to $4M over the past 5 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -10.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -10.0%, indicating a declining trend.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.2M | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $7.7M | +8.3% |
| FY2020 | $7.1M | +433.8% |
| FY2019 | $1.3M | +49.3% |
| FY2018 | $896.0K | +745.3% |
| FY2017 | $106.0K | +17.8% |
| FY2016 | $90.0K | +0.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026